ArticleBMC medical genomics2026
SomaScan proteomics reveals novel biomarkers in the progression of liver cirrhosis to hepatocellular carcinoma.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Relevance of Neddylation-Related Genes in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) typically develops from liver cirrhosis (LC), however early diagnosis is difficult due to a lack of reliable biomarkers. The goal of this study was to use SomaScan proteomics technology to find plasma protein profiles that differentiated LC and HCC from healthy controls in order to develop novel biomarkers for HCC early detection and targeted therapy.
methodsWe used SomaScan technology to evaluate 10,893 plasma proteins from LC, HCC, and normal populations. Differentially expressed proteins (DEPs) were discovered and functionally annotated using HPA, GO/KEGG, and PPI networks. Venn analysis was used to identify DEPs that were expressed in both LC and HCC.
resultsThere were 402 DEPs in LC and 389 in HCC, with MAPK signaling and neutrophil extracellular trap generation being the primary dysregulated pathways in LC and HCC, respectively. In addition, 38 co-expressed DEPs (e.g., SSX7, HIP1R, SLC25A18) were discovered in LC and HCC, including 9 previously unknown potential DEPs. PPI network analysis revealed that FLT4 and PDGFA were key drivers of LC progression to HCC. ELISA experiments confirmed that FLT4 and PDGFA are consistently down-regulated in the progression of LC to HCC (P < 0.05).
conclusionsThis investigation described the plasma proteomes of LC and HCC and identified FLT4 and PDGFA as possible early screening targets for HCC, establishing a scientific foundation for HCC detection in high-risk LC populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.